Oral hypoglycaemics: A review of the evidence

Australian Family Physician

Volumn 39, Issue 9, 2010, Pages 651-653

  Phillips, Patrick J ^a   Twigg, Stephen M ^b,c  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Diabetes mellitus; Glitazones; Hypoglycemic agents; Type 2 therapy

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; GLYCOSYLATED HEMOGLOBIN; SULFONYLUREA DERIVATIVE;

DRUG POTENTIATION; HUMAN; LIFESTYLE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; REVIEW; RISK FACTOR;

ADMINISTRATION, ORAL; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LIFE STYLE; RISK FACTORS; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 77957329110     PISSN: 03008495     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. Harris P, Mann L, Marshall P, Phillips PJ, Webster C. Diabetes management in general practice. Guidelines for type 2 diabetes. The Royal Australian College of General Practitioners. Diabetes Australia. [14th] edition 2009-2010.
2. MIMS. Australia prescribing information Avandia (rosiglitazone maleate). MIMS 2009;5:237.
3. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71.
4. Singh S, Loke YK, Fuberg CD. Long term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007;298:1189-95.
5. Holme PD, Peacock SJ, Beck-Nielson H, et al. Rosiglitazone Evaluation for Cardiovascular Outcomes in Oral Combination Therapy for Type 2 Diabetes (RECORD): a multicentre, randomized, open label trial. Lancet 2009;373:2125-35.
6. Therapeutic Goods Administration. Avandia (rosiglitazone maleate) product information. Issue No. 13(M). Date of TGA approval: 8 November 2007.
7. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298:1180-8.
8. Erdmann E, Charbonnel B, Wilcox RG, et al. Pioglitazone use and heart failure in patients with type 2 diabetes and pre-existing cardiovascular disease. Diabetes Care 2007;30:2773-8.
9. Y eap BB. Controversies in type 2 diabetes. Aust Fam Physician 2009;38:22-5.
10. Grey A. Skeletal consequences of thiazolidinedione therapy. Osteoporosis Int 2008;19:129-37.
11. Therapeutic Goods Administration. Actos (pioglitazone hydrochloride) product information. Date of TGA approval: 20 November 2007.
12. Fulcher G. A combination approach to targeting type [2] diabetes. Diabetologia 1986;29:46-52.
13. Prins J. Incretins mimetics and enhancers: mechanisms action. Australian Prescriber 2008;31:102-4.
14. National Prescribing Service. Dipeptidyl peptidase-4 inhibitors ('gliptins') for type 2 diabetes mellitus. RADAR 2010. Available at www.nps.org.au/health_professionals/publications/nps_radar/2008/august_2008/gliptins.
15. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203.
16. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. Ten year follow up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89.
17. The Action to Control Cardiovascular Risk in Diabetes Study Group. Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. New Engl J Med 2008:358:2545-59.
18. ADVANCE Collaborative Group. Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New Engl J Med 2008;358:2560-72.
19. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-39.
20. Twigg S. Glycaemic targets in type 2 diabetes after the ACCORD and ADVANCE studies. Diabetes Management Journal 2008;24:32.